Peptide-GlcN Prodrug Enhances Bioavailability and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Glucosamine (GlcN) products for treating osteoarthritis and rheumatoid arthritis have inconsistent results due to low bioavailability, physical instability, and questionable quality, leading to the need for high doses and poor patient compliance.
Innovation Solution
Development of peptide-GlcN ester and amide derivatives, such as Gly-Val-COO-GlcN (GV-GlcN), which are physicochemically stable, efficiently absorbed, and converted to GlcN in the liver, providing higher bioavailability and therapeutic benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high doses of GlcN are administered to achieve therapeutic effects, then plasma GlcN concentration increases, but patient compliance deteriorates due to large tablet size and frequent dosing requirements
Solution Approach 1:
The patent changes the chemical structure parameter by converting GlcN into a prodrug form (GlcN-OSO2R ester) with improved physicochemical properties. This molecular modification enables the compound to achieve therapeutic plasma concentrations at lower doses while maintaining stability and bioavailability, directly resolving the contradiction between achieving effective concentrations and patient compliance
Solution Approach 2:
The prodrug is designed with a precursor structure that undergoes in vivo conversion to the active GlcN form. This preliminary chemical preparation allows the compound to be absorbed more efficiently and converted systemically, achieving therapeutic effects with smaller, more compliant dosing regimens rather than requiring large doses of unstable GlcN
2Stability of the object's composition
If GlcN is crystallized to improve physical stability, then storage stability improves, but tablet size increases due to co-crystallization with KCl
Solution Approach 1:
The patent modifies the chemical structure by converting GlcN into an ester prodrug form (GlcN-OSO2R), which fundamentally changes the physicochemical properties including solubility, stability characteristics, and molecular weight. This parameter change eliminates the need for co-crystallization with KCl while maintaining physical stability, thereby reducing tablet size and improving patient compliance
3Quantity of substance
If pro-drug design is implemented to improve bioavailability, then plasma concentration increases, but molecular complexity increases
Solution Approach 1:
The patent applies parameter changes by modifying the GlcN molecule with a specific ester group (OSO2R) that provides improved bioavailability and stability. This targeted molecular modification achieves the desired pharmacokinetic improvements without excessive complexity, balancing enhanced performance with manageable molecular structure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
GV-GlcN exhibits significantly higher bioavailability and therapeutic potency compared to GlcN, effectively preventing and controlling adjuvant arthritis, with reduced paw thickness and increased plasma concentrations, demonstrating a three-fold greater potency than GlcN.
Implementation Method 1
Efficient conversion to GlcN in the liver, consequently delivering high amounts of GlcN to the systemic circulation
Data Source
AI summary
To develop glucosamine (GlcN) pro-drugs with properties superior to the presently available GlcN products, we have synthesized derivatives with improved pharmaceutical properties. The synthesized derivatives include peptide-GlcN ester and amide conjugates where the peptide portion consists of one or more amino acids. One such compound is (5-amino-3,4,6-trihydroxyoxan-2-yl)methyl 2-(2-aminoacetamido)-3-methylbutanoate or glycine-valine-COO-GlcN (GV-GlcN).7.